Efficacy and Mechanism of Action of SCIg in Patients With Stiff Person Syndrome (SPS)

NCT ID: NCT03829826

Last Updated: 2019-05-14

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 22 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-06-30
• Study Completion Date: 2020-05-31

Brief Summary

This is a pilot, proof-of concept investigator-initiated trial planned for 22 patients with the diagnosis of Stiff Person Syndrome (SPS). The study will compare efficacy of treatment using subcutaneous immunoglobulin therapy (SCIg) compared to intravenous immunoglobulin (IVIg) therapy. The majority of IVIg naïve subjects (those not already receiving IVIg) are typically managed with non-immunotherapy mostly Gamma Aminobutyric Acid (GABA) -enhancing drugs such as Baclofen or Diazepam.

Detailed Description

Study Design:This is a proof of concept observational prospective, open label, study on the safety, efficacy and convenience of treatment with SCIg study of 22 patients at Thomas Jefferson University Hospital. Two cohorts of patients within the total of 22 will be included; half of them (11 patients) currently receiving and responding to IVIg and the other half starting de novo on SCIg. Patients diagnosed with SPS according to defined sets of symptoms will be eligible to enroll.

The primary clinical outcome will be based on clinical efficacy measures, as used before for the IVIg trial, based on changes in the Stiffness Index and Heightened Sensitivity scores, using the validated scales that the investigators have had previously utilized and validated (Dalakas et al 2001; see attached at the end of the protocol). These same measurements will be applied while on IVIg (weeks 0, 4, 8, 12) and will be compared to the measurements obtained during SCIg (weeks 16, 20, 24, 28). The secondary outcome will be Quality of Life (QoL) responses and patient preference for each treatment.

Conditions

Stiff-Person Syndrome

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients receiving IVIg

Patients are currently receiving IVIg regularly for at least every 6 weeks and exhibit a favorable response will be recruited into the study (11 patients). They will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their impairment using the previously validated Stiffness and Sensitivity scales and quality of life questionnaire (QoL) at weeks 0, 4, 8, 12. At week 12, prior to the first SCIg infusion, blood will be drawn for humoral (immunological) studies. One week following the last dose of IVIg (at week 13), the participants will be started on SCIg at a total dose equivalent to the monthly dose of IVIg they have been receiving.

HyQvia

Intervention Type: BIOLOGICAL

Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

de novo SCIg patients/IVIg-Naive Group

This other arm of the trial will include 11 patients naïve to IVIg who do not receive other immunotherapies while being symptomatic. These patients after a 12-week observation period will start directly on SCIg drug (HYQVIA), following the same schedule as described above for the previous group.

HyQvia

Intervention Type: BIOLOGICAL

Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

Interventions

HyQvia

Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Men or women aged >18 years
• Diagnosis of SPS based on standard criteria
• IVIg Group: Receiving the equivalent of 1-2 g/kg IVIg every 4 weeks with dependence* on IVIg to maintain clinical response *Dependence is clinically determined either by symptomatic worsening of condition at the end of the inter-dose interval or by worsening after dose reduction or discontinuation within the previous 3 months.
• IVIg-Naïve Group: Patients with symptomatic SPS and never treated with IVIg (IVIg-naïve group), poorly controlled with standard therapy

Exclusion Criteria

• Pregnancy, planned pregnancy, breast-feeding or unwillingness to practice contraception
• Severe concurrent medical conditions, which would prevent treatment or assessment, including significant hematological, renal or liver dysfunction or malignancies
• Initiation of immunomodulatory treatment other than IVIg in the past 3 months
• Participation in a trial of an investigational medicinal product in the past 12 weeks
• Presence of any medical condition, which in the opinion of the investigator might interfere with performance or interpretation of this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Thomas Jefferson University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Marinos C Dalakas, MD

Role: CONTACT

marinos.dalakas@jefferson.edu

2159557865

Vikram Puvenna

Role: CONTACT

vikram.puvenna@jefferson.edu

2159554672

Other Identifiers

18P.420

Identifier Type: -

Identifier Source: org_study_id